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Low-level doxorubicin resistance in P-glycoprotein-negative human
pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive
mechanism of drug extrusion
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'Cancer Research Unit, Department ofRadiotherapy, Academic Hospital, Free University Brussels, 1090 Brussels, Belgium;
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Summary The human pancreatic tumour cell line PSN1/ADR, stepwise selected in 17-510 nM doxorubicin,
displayed a multidrug resistance not conferred by P -glycoprotein (P -gp). Resistance to 17-51 nM doxorubicin
was accompanied by overexpression of the vesicular marker lung resistance-related protein (LRP). Further
selection in 170 nM doxorubicin led to the activation of multidrug resistance-associated protein (MRP) and to
the development of drug accumulation/retention defects sensitive to verapamil. In addition, these defects were
reversible by the vesicular traffic inhibitors brefeldin A, fluoroaluminate and nocodazole. In contrast, in human
ovarian H134AD cells that are resistant to 1700 nM doxorubicin and used as P-gp-positive controls, the drug
efflux was inhibited only by verapamil. The tyrosine kinase inhibitor genistein was a potent blocker of
doxorubicin efflux in the PSN1/ADR cells but showed no activity in the H134AD cells. The doxorubicin
cytotoxicity in the PSN1/ADR cells was enhanced both by verapamil and brefeldin A, whereas in the parental
PSNI cells they demonstrated the opposite effects, being respectively sensitising and protecting. The P-gp-
negative PSN1/ADR cells adapted to 510 nM doxorubicin retained brefeldin A-sensitive doxorubicin
accumulation defects while MRP declined. The persistence of brefeldin A-responsive phenotype on the
background of variable MRP expression suggests this agent as a useful functional probe for non-P-gp-
mediated resistance to plasma-achievable doxorubicin concentrations.
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Overexpression of the 170 kDa transmembrane transporter
P-glycoprotein (P-gp) has been implicated in multidrug
resistance (MDR) associated with an accelerated outward
drug transport (Gottesman and Pastan, 1993). Recently, new
mediators of MDR were identified in P-gp-negative tumour
cells resistant to doxorubicin (DOX), indicating differential
mechanisms of drug extrusion. The 190 kDa multidrug
resistance-associated protein (MRP), a novel member of the
ABC transporters, appears to precede P-gp activation or to
function solely in MDR clones (Cole et al., 1992; Flens et al.,
1994; Eijdems et al., 1995). The MRP and P-gp efflux pumps
confer a similar MDR phenotype (Cole et al., 1994), whereas
the 190 kDa transporter seems to possess a reduced substrate
specificity for the fluorescent dye rhodamine 123 (Twentyman
et al., 1994) and the competitive inhibitor verapamil
(McGrath et al., 1989; Barrand et al., 1993). An alternative
mechanism of anthracycline sequestration away from nuclear
targets is supposed to involve the vacuolar system and
vesicular secretory traffic (Beck, 1987). The latter model is in
agreement with the following observations: increased
membrane exocytosis in MDR cells (Sehested et al., 1987);
anthracycline accumulation in vesicular compartments
(Gervasoni et al., 1991; Coley et al., 1993); restoration of
cellular or nuclear drug accumulation induced by the
protonophores nigericin and monensin (Marquardt and
Center, 1992), by the inhibitor of vesicular exocytosis
brefeldin A (BFA), and by the H+-ATPase inhibitor
bafilomycin Al (Rhodes et al., 1994). Several P-gp-negative
MDR tumour cell lines and secretory epithelia were reported
to overexpress the 110 kDa lung resistance-related protein
(LRP), a vesicle marker with unknown function (Scheper et
al., 1993). Whatever putative mediators are found over-
expressed in MDR clones, the major problem to resolve is
their relevance to clinical drug resistance. Indeed, inherent
DOX resistance of solid tumours apparent within drug
concentrations achievable in plasma may not be conferred
by P-gp, which is normally activated in vitro under high
selection pressure of over 500 nM DOX at continuous
exposure. The early stages in MDR selection are likely to
provide more valuable insights into mechanisms of drug
extrusion operating in chemoresistant tumours.
In a preliminary report we showed that MDR in the
human pancreatic tumour PSN1/ADR cells selected by
intermittent exposure to 170 nM DOX was not the result of
P-gp expression, and that increased DOX efflux in these cells
was inhibited by BFA (Verovski et al., 1994). BFA is a
potent inhibitor of vesicle budding and exocytosis (Klausner
et al., 1992). It disrupts the downstream GDP/GTP signal
towards the ADP-ribosylation factor (ARF), a monomeric
GTP-binding (G) protein, triggering vesicle budding
(Donaldson et al., 1992). An upstream regulation of vesicle
budding implicates heterotrimeric G proteins sensitive to
fluoroaluminate, an agent that abrogates the GDP/GTP
exchange by mimicking the y-phosphor in GTP (Barr et al.,
1991). Thus, BFA and fluoroaluminate can be considered as
probes for the G protein-controlled vesicular traffic whose
possible function in drug trapping and extrusion may be to
adjunct the ATP-dependent drug translocations through the
P-gp and MRP efflux pumps. The anterograde transport of
vesicles is driven along cytoskeletal microtubules and can
therefore be inhibited by nocodazole, a microtubule-
disrupting agent (Breitfeld et al., 1990).
Based on the hypothesis that G protein-dependent drug
transport pathways may contribute to low-level DOX
resistance, we took a further step to characterise the
immunocytochemical and pharmacological profile of the
PSN1/ADR cells. Therefore, the evolution of DOX
resistance, P-gp/MRP expression and the effects of BFA
and fluoroaluminate on DOX accumulation have been
analysed in several PSN1/ADR sublines stepwise selected in
clinically relevant drug concentrations. The MDR phenotype
of PSN1/ADR cells was verified using a broad spectrum of
anti-tumour drugs. In addition, the mechanisms of DOX
extrusion in the MRP-positive PSN1/ADR and the P-gp-
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positive H134AD cells were explored using the functional
probes for drug transporters and vesicular traffic briefly
described above. The tyrosine kinase inhibitor genistein was
involved in this study since it was recently shown to inhibit
specifically anthracycline efflux in MRP-positive MDR cells
(Versantvoort et al., 1993).
Material and methods
Chemicals
Doxorubicin was purchased from Farmitalia Carlo Erba
(Milan, Italy) as the clinical preparation (2 mg ml-'). Other
drugs and chemicals were obtained from Sigma Chemical (St
Louis, MO, USA) unless otherwise stated. The stocks of
BFA, genistein and nocodazole were prepared in dimethyl
sulphoxide (DMSO) and kept frozen at -20°C. Fluoroalu-
minate was obtained by mixing aluminium chloride and
sodium fluoride at a molar ratio of 1:1000 and final
concentrations of fluoroaluminate (AIF4-) were equalised to
those of aluminium chloride. Other drugs and modulators
were freshly dissolved in water or phosphate-buffered saline
(PBS) before serial dilution in growth medium.
Cell culture
The human pancreatic tumour cell line PSN1 was originally
established from a ductal pancreatic adenocarcinoma by Dr
H Kalthoff (Department of Immunology, Eppendorf Uni-
versity Hospital, Eppendorf, Germany) and kindly provided
by Dr G Kl6ppel (Department of Pathology, Academic
Hospital, Free University of Brussels, Brussels, Belgium).
PSN1/ADR is a P-gp-negative subline established in our
laboratory from PSN1 by stepwise selection in DOX
concentrations at 17, 51, 170 and 510 nM during passages
1-5, 6-30, 31-90 and 91-125 respectively. The selection
procedure was based on a 24 h drug exposure protocol
followed by 6 days of recovery in drug-free medium. The
PSN1/ADR sublines at the passages 17, 54, 90 and 125,
which were chosen for pharmacological/immunocytochemical
assays have acquired respectively 7.3-, 17-, 33- and 96-fold
drug resistance based on IC50 values at continuous exposure.
The sublines were designated by their resistance indices
following the symbol ADR (adriamycin). The P-gp-positive
MDR human ovarian tumour cell line H134AD, maintained
in 1700 nM DOX, and the parental cell line H134 were
originally established by Dr HJ Broxterman (Department of
Medical Oncology, Free University Hospital, Amsterdam, the
Netherlands) and kindly provided by Dr H Heyligen
(Department of Monoclonal Antibodies, Dr L Willems
Institute, Diepenbeek, Belgium). The adherent cultures of
all cell lines were maintained in RPMI-1640 medium (Gibco,
Paisley, UK) supplemented with 10% bovine calf serum
(HyClone Laboratories, Logan, UT, USA) at 37°C in 5%
carbon dioxide/95% air. Other characteristics of the cell lines
have been reported elsewhere (Scheper et al., 1988, 1993;
Maillet et al., 1993). All studies were carried out in early
confluent cultures on plastic tissue culture plates (Greiner,
Frickenhausen, Germany).
Immunostaining
To perform immunostaining, cells were fixed with 4%
paraformaldehyde and permeabilised with 0.1% saponin. P-
gp, LRP and MRP were stained respectively with monoclonal
antibodies JSB-1 (Scheper et al., 1988), LRP-56 (Scheper et
al., 1993) and MRPm6 (Flens et al., 1994) at dilution 1:100
overnight at 4°C. All antibodies were provided by Dr RJ
Scheper. The secondary FITC-conjugated antibodies were
isotype specific and purchased from Seralab (Sussex, UK)
and Southern Biotechnology Associates (Birmingham, AL,
USA). The secondary antibodies were used at a 1:200
dilution for 3 h at 20°C. The level of immunostaining was
estimated by flow cytometry as the mean fluorescence channel
in a FACS 4 (Becton Dickinson, Mountain View, CA, USA).
Cytotoxicity assays
The drug cytotoxicity (IC50) at continuous exposure was
estimated by a 5 day MTT assay as described previously
(Delvaeye et al., 1993). The surviving fraction (SF) of cells
exposed to DOX for 4 h was assessed by a modified MTT
serial dilution assay carried out as follows. Confluent
cultures of PSN1 and PSN1/ADR cells were exposed to
DOX at concentrations indicated in the legends, washed
with PBS and harvested by trypsinisation. Six serial dilutions
(0.5 log-fold) of the cell suspension, starting from 104 cells
per well, were reseeded into a 96-well plate and incubated
for 5 days. The MTT assay was performed for 3 h at 37°C
in 80 pl of fresh medium containing 0.5 mg ml-' MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide].
The reaction was stopped by careful addition of 200,l of
DMSO - 0.05 M HCl. The formazan crystals were dissolved
in the lower layer of DMSO during 5- 10 min at 37°C.
Afterwards the DMSO and medium layers were mixed by
repeated pipetting and the absorbency was measured at
540 nm. The surviving fraction (SF) was calculated as the
dilution factor of the control that produced the same optical
density as the treated samples.
Doxorubicin accumulation
Cell cultures were exposed to 1 jg ml-' DOX alone or with
modulators at specified concentrations for 4 h at 37°C and
washed with PBS on ice. The incubation period of 4 h was
selected in preliminary experiments as the end point,
corresponding to a steady-state cellular drug concentration.
The cellular DOX content was estimated by a fluorometric
assay in a 50% ethanol/0.05 N HCI extract and normalised
to DNA (ng DOX pg-' DNA) as described previously
(Delvaeye et al., 1993). We preferred to use the DNA
content rather than the cell count to normalise the DOX
uptake because the adherent cells were fixed by the ethanol
extraction procedure and therefore difficult to resuspend.
Doxorubicin retention
The cell cultures were exposed to 10 jg ml-' DOX for 1 h at
37°C, washed with PBS and reincubated for 2 h at 37°C in
drug-free medium with modulators at the indicated concen-
trations. The incubation time of 2 h was selected in
preliminary experiments as the end point providing a
reasonable divergence of the drug retention-time curves for
PSN1 and PSN1/ADR cells. Afterwards, the cells were
washed with PBS on ice and processed for analysis of the
cellular DOX content as in the DOX accumulation
experiments. The cellular DOX content after a 1 h uptake
was taken as 100%.
Rhodamine 123 uptake
Cell cultures were exposed to 0.2 ug ml-' rhodamine 123 for
1 h at 37°C, washed with cold PBS and trypsinised. The
intracellular rhodamine 123 content was analysed by flow
cytometry in a FACS 4.
ECL Western immunoblotting
Cells were lysed in a buffer containing 137 mM sodium
chloride, 20 mM Tris-HCl (pH 8.0), 1% triton X-100, 0.5%
deoxycholate, 0.1% SDS, 1 mM phenylmethylsulphonyl
fluoride, 1 jig ml-' aprotinin and 1 jg ml-' pepstatin. The
lysates were sonicated, clarified for 20 min at 13 000 g and
mixed 1:4 (vol/vol) with a standard SDS/2-mercaptoethanol-
containing sample buffer. The protein extracts from 105 cells
were resolved in an SDS/PAGE using a 7.5% resolving gel
(1.5 mm thickness), and electrophoretically transferred onto
Hybond-C super nitrocellulose membrane (Amersham,
Buckinghamshire, UK). The membranes were stained for
1 h at 20°C with the primary monoclonal antibodies to P-gp
(JSB-1, 1:300) and MRP (MRPm6, 1:100). The blots wereEffect of brefeldin A on doxorubicin extrusion
VN Verovski et at
598
analysed by an immunoperoxidase-based ECL technique
(Amersham) according to the manufacturer's protocol.
Statistics
All assays were repeated 3-6 times. Data are expressed as
arithmetical means (points) with corresponding standard
deviations (bars).
Results
Immunocytochemical andpharmacologicalphenotype ofPSNI/
ADR cells
PSN1/ADR cells selected in 17-51 nM DOX showed the
activation of LRP but not MRP as assessed by FACS and
shown for the PSN1/ADR7.3 subline in Figure 1. Further
selection in 170 nM DOX (sublines PSNl/ADR17 and PSNI/
ADR33) led to the activation of MRP, whereas the LRP level
remained stable. The acquisition ofdrug resistance to 170 nM
DOX was caused by DOX accumulation defects reversible by
10 gM verapamil, 320 gM BFA and 10 4UM fluoroaluminate.
In the parental PSN1 cells the DOX uptake was increased
only by verapamil, whereas BFA at 10 ,uM caused a small but
distinct protective effect resulting in a 20+9.0% decrease
a
cL 75-
QC _D
c
0Q0) , 50-
o 2
cx:
0 = ) ' w00 2
- D rt RADD M I DD
(P<0.05) in cellular DOX content. The immunoblot data on
MRP and P-gp expression were in agreement with FACS
analysis, and the presence of a low but detectable level of
MRP in the parental PSN1 cells was observed (Figure 2).
MRP immunostaining in PSN1 cells was clearly positive
upon ECL overexposure (3 min instead of 15 s), while P-gp
remained undetectable (data not shown). PSNI/ADR96 cells,
selected in 510 nM DOX, retained a P-gp-negative phenotype
while MRP expression was reduced. The DOX accumulation
defects remained sensitive to verapamil, BFA and fluoroalu-
minate with a maximal response to chemomodifiers at a 4-
8 h exposure, corresponding to the steady-state level of
cellular DOX concentrations (Figure 3). These kinetics were
similar in all of the PSN1/ADR sublines (data not shown).
The H134AD cells originally selected in 1700 nM DOX
overexpressed P-gp (Figure 2) in agreement with literature
(Scheper et al., 1988). The latter cells were used in this study
as a model of P-gp-mediated DOX resistance.
Flow cytometry of the rhodamine 123 uptake
The fluorescent dye rhodamine 123 is thought to be a
relevant probe for the P-gp efflux pump and provides a
sensitive functional assay, alternative to immunostaining
approaches (Gottesman and Pastan, 1993). Indeed, the
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Figure 2 Western blot analysis of the MRP (a) and P-gp (b)
expression in H134AD and PSN1 cells and the PSN1/ADR
sublines named according to their doxorubicin resistance index.
The protein samples extracted from 105 cells were resolved in a
7.5% polyacrylamide gel containing 0.1% SDS. The blots were
probed for P-gp and MRP with the monoclonal antibodies JSB-1
and MRPm6 respectively and analysed by an immunoperoxidase-
based ECL technique.
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Figure 1 Evolution of immunocytochemical phenotype (a) and
doxorubicin accumulation defects (b) in the human pancreatic
tumour PSN1/ADR cells during the course of stepwise selection
in 17-170nm doxorubicin. (a) P-gp, MRP and LRP expression
was measured by FACS, using the monoclonal antibodies JSB-1,
MRPm6 and LRP-56 respectively. (b) The doxorubicin accumula-
tion defects were probed with brefeldin A, fluoroaluminate and
verapamil in a 4h drug accumulation assay. The cells were
exposed to 1.0Mgml-1 doxorubicin alone or in combination with
modulators at the indicated concentrations and the cellular
doxorubicin content was normalised to DNA. Doxorubicin
resistance index 1 corresponds to the parental PSN1 cells. The
resistant sublines are indicated by their resistance indices (7.3, 17
and 33) and are named later PSN1/ADR7.3, PSNl/ADR17 and
PSN1/ADR33.
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Figure 3 The kinetics of doxorubicin accumulation in PSN1/
ADR96 cells. The cellular doxorubicin content was measured
during exposure to 1 Mgml-' doxorubicin alone (- - -) or in the
presence of 10.M fluoroaluminate (El), 10 M verapamil (0) or
3201iM brefeldin A (A\).
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Figure 4 Flow cytometry of the rhodamine 123 uptake in
H134AD cells, in the PSN1/ADR sublines and in the parental
cells. Representation of a typical cell population analysis after
exposure of cell cultures to 0.2Mgml-1 of rhodamine 123 for 1 h.
The position of all blanks (not exposed to rhodamine 123) was
adjusted to that of the H134 cells.
rhodamine 123 uptake was significantly reduced in the P-gp-
positive H134AD cells relative to the H134 cells (Figure 4).
To compare the FACS data, all blank samples (not exposed
to rhodamine 123) were adjusted to that of H134 cells by
tuning the amplification of the fluorescence signal. In contrast
to H134AD cells the rhodamine 123 signal in the MRP-
positive PSN1/ADR sublines was close to that of the parental
cell line PSNI, although for the PSN1/ADR33 cells we
observed a somewhat decreased rhodamine 123 uptake. This
comparison confirms the low activity of the P-gp pump in
PSN1/ADR cells as expected from the immunostaining
experiments (Figures 1 and 2).
Drug cross-resistance in PSNI/ADR cells
The PSNI/ADR33 cells selected in 170 nM DOX demon-
strated an MDR phenotype with classical cross-resistance to
natural cytotoxins including etoposide, vincristine and
actinomycin D (Table I). The resistance index (7.6- to 39-
fold) between the PSNI/ADR33 and PSNI cells could not be
attributed to any differences in growth rate since both cell
lines possessed the same doubling time of 21+2 h. A much
lower resistance index was observed for colchicine and
rhodamine 123, being respectively 4.3 and 3.9. There was
also a weak cross-resistance (3.1-fold) to cisplatin, a drug that
is not normally involved in MDR. BFA and genistein did not
show cross-resistance to DOX and revealed spectacular
difference in cytotoxicity at continuous exposure in contrast
to growth inhibition effects at a short-term exposure (see
below).
Effects ofbrefeldin A and verapamil on doxorubicin
cytotoxicity
The high cytotoxicity of BFA at continuous exposure did not
allow us to conduct chemosensitising experiments using a
Table I Drug cross-resistance in PSN1 and PSN1/ADR33 cells
IC50 (,M)a
Drugs PSNI PSNI/ADR33 Ri
Etoposide 0.17+0.026 6.7+1.5 39
Doxorubicin 0.0082+ 0.00055 0.27 + 0.036 33
Daunorubicin 0.0094+0.00063 0.11 ±0.045 12
Vincristine 0.00079 ±0.000056 0.0076+ 0.0036 9.6
Actinomycin D 0.00025+0.000096 0.0019±0.00041 7.6
Colchicine 0.0097±0.0021 0.042+0.0076 4.3
Rhodamine 123 0.70+0.11 2.7+0.29 3.9
Cisplatin 0.14+0.015 0.43±0.15 3.1
Taxol 0.0039+0.00059 0.0067±0.0039 1.7
Mitomycin C 0.033 ±0.0035 0.053+0.003 1.6
Fluoroaluminate 0.77±0.22 1.1 +0.047 1.4
5-Fluorouracil 0.73 ±0.11 0.80 ±0.39 1.1
Nocodazole 0.049+0.0012 0.054+0.0021 1.1
Amsacrine 4.6+0.75 4.8+0.23 1.0
Genistein 36+4.2 37± 3.5 1.0
Verapamil 71 i 1.7 70±6.6 0.99
Brefeldin A 0.064+0.011 0.060±0.012 0.94
aIC50, drug cytotoxicity was determined at continuous exposure
using a 5 day MTT assay. bRI, the resistance index, was calculated by
dividing the IC50 value ofPSNl/ADR33 cells (passage 90) by the IC50
value ofthe parental PSN1 cells.
classical MTT assay. Therefore, confluent cultures of PSN1
and PSN1/ADR33 cells were exposed to DOX and
chemomodifiers for 4 h and afterwards the cells were
reseeded to assess the cell survival (Table II). As in the
pharmacological studies, BFA demonstrated both a sensitis-
ing or a protective effect, depending on the drug resistance
level. In the PSN1 cells BFA at 10-32 gM reduced the DOX
cytotoxicity by 2.1 to 2.4-fold. In the PSN1/ADR33 cells,
BFA at a maximal non-cytotoxic concentration of 320 giM
(SF>0.8 for BFA alone) increased the DOX cytotoxicity by
2.5-fold. In contrast to BFA verapamil sensitised both the
PSN1 and PSN1/ADR33 cells with a preferential reversal
effect in the latter cells. The sensitisation index of verapamil
and BFA in the PSN1/ADR33 cells was approximately equal
and rather modest compared with the level of acquired
resistance. Genistein at active modulatory concentrations of
100-320 gM demonstrated a delayed cytotoxicity (SF<0.8
alone) and therefore was not assessed as a reverser of DOX
resistance.
Doxorubicin retention in the PSNI/ADR and H134AD cells
The mechanisms of DOX extrusion in the MRP-positive
PSN1/ADR33 cells and in the P-gp-positive H134AD cells
were probed by diverse inhibitors of drug transporters and
vesicular traffic. To compare a modulatory potency, agents
were tested in the range of at least 10-fold dilutions using a
fixed 2 h time point in the DOX retention assay (Figure 5).
Genistein and BFA decreased the DOX efflux in the PSNl/
ADR33 but not H134AD cells with identical specificity and
molar inhibitory potency. Fluoroaluminate and nocodazole
were also potent inhibitors of the DOX efflux only in the
Table H Effect of brefeldin A and verapamil on doxorubicin cytotoxicity in PSN1 and PSN1/ADR33 cells.
PSN1/ADR33 PSN1
Treatment SFr SJ SF SI
DOX alone 0.43 ±0.065c 1.0 0.084±0.018 1.0
DOX+ 10 Mm verapamil 0.19± 0.032c 2.3 0.056+ 0.014c 1.5
DOX+ 10 Mm BFA 0.36±0.070 1.2 0.20 ±0.066c 0.42
DOX+32 ,M BFA 0.28+0.051C 1.5 0.18±0.044c 0.47
DOX+100 gM BFA 0.23+0.027c 1.9 0.15±0.027c 0.56
DOX +320 gM BFA 0.17+0.031c 2.5 0.12i0.018c 0.70
10 gM verapamil alone 0.98+0.051 0.99+0.072
320 FM BFA alone 0.88 i0.12 0.93 ±0.093
'SF, survival fraction ofcells after4 hdrugtreatmentwasestimated by the MTT serial dilution assay.PSN1 andPSN1/ADR33 cells (passage 90)
were exposed to doxorubicin alone at 0.1 and 1.0 Mgml'- respectively or in combination with brefeldin A or verapamil at the specified
concentrations. bSI, the sensitisation index, wascalculated by dividingthe SF fordoxorubicin alone by the SF fordoxorubicin pluschemomodifier. CP<0.01 compared with doxorubicin alone.Effect of brefeldin A on doxorubicin extrusion
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PSN1/ADR33 cells. The effects of fluoroaluminate and
genistein should be interpreted with caution since they are
somewhat cytotoxic at modulatory concentrations (data not
shown). It is worth noting that verapamil was a rather non-
specific inhibitor of the DOX efflux in both drug-resistant cell
lines, and was unexpectedly more active in the MRP-positive
PSN1/ADR33 cells. However, the restoration of DOX
retention by verapamil in the latter cells did not result in a
substantial chemosensitisation, as shown in Table II. The
DOX retention levels in the parental PSN1 and H134 cells
were 63+6.2 and 58+4.1% respectively. The modulatory
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Figure 5 Modulation of doxorubicin efflux in PSNI/ADR33 and
H134AD cells by brefeldin A (0, a) genistein (0, a),
fluoroaluminate (b), nocodazole sc) and verapamil (d). Cell
cultures were exposed to 10Oug ml- doxorubicin for 1 h, washed
with PBS and reincubated for 2h in drug-free medium with or
without a modulator. The cellular doxorubicin content is
expressed as a percentage relative to the amount after 1 h
uptake. (-
- -), Level of doxorubicin retention in the absence of
chemomodifiers.
effects of all inhibitors in these cells were below 25% and are
not presented here. The comparison of DOX accumulation -
retention patterns in the PSNI and PSNI/ADR33 cells
clearly demonstrated an accelerated drug extrusion as the
mechanism of reduced drug accumulation and acquired DOX
resistance.
Discussion
Selection of the human pancreatic tumour cell line PSN1/
ADR in 17-510 nM DOX activated various MDR markers
and mechanisms of drug resistance without inducing a
detectable level of P-gp. In both flow cytometry and ECL
Western blot immunostaining the PSN1/ADR33 cells
adapted to 170 nM DOX at intermittent exposure displayed
a rise in MRP only. The P-gp efflux pump remained
undetectable by the rhodamine 123 functional assay
(Gottesman and Pastan, 1993). The DOX accumulation-
retention defects in the MRP-positive PSN1/ADR33 cells
were reversible by the vesicle traffic inhibitors BFA and
fluoroaluminate. In contrast, in the P-gp-overexpressing
H134AD cells adapted to 1700 nM DOX at continuous
exposure (Scheper et al., 1988), rhodamine 123 uptake was
significantly decreased, while both BFA and fluoroaluminate
failed to inhibit DOX extrusion. Therefore, our data suggest
that the BFA/fluoroaluminate-sensitive mechanism of DOX
extrusion plays a role in low-level DOX resistance associated
with the MRP transporter, but may be attenuated in highly
resistant clones possessing the more efficient P-gp efflux
pump. A prevalent role of MRP over P-gp in early steps of
MDR acquisition emerged in recent literature (Eijdems et al.,
1995). Another early MDR marker found in P-gp-negative
MDR clones seems to be LRP (Scheper et al., 1993), which
we observed already in PSN1/ADR7.3 cells selected in 17-
51 nM DOX. While the function of LRP is not known, the
MRP transporter can confer broad-spectrum MDR (Cole et
al., 1994), and is likely to underlie the MDR phenotype of
PSN1/ADR33 cells. The MRP-positive PSN1/ADR33 cells
exhibit an MDR spectrum similar to P-gp-mediated MDR
(Gottesman and Pastan, 1993) except for an unusual cross-
resistance to cisplatin, reported also for the P-gp-negative
N592/DX cells (Supino et al., 1993).
The reversal effects of chemomodifiers in 190 kDa/MRP-
overexpressing cells appear to be reduced and more variable
than in P-gp-positive MDR cells (McGrath et al., 1989;
Barrand et al., 1993; Versantvoort et al., 1993; Cole et al.,
1994). In our experiments with MRP-positive PSN1/ADR33
cells the reversal effect of verapamil on DOX resistance was
modest relative to the magnitude ofacquired resistance. In the
parental PSN1 cells verapamil also demonstrated sensitising
effects, whereas BFA caused chemoprotection. The lattereffect
has been previously described in L1210cells (Vichi andTritton,
1993). Important findings are that BFA possesses a reversing
activity similar to that ofverapamil in PSN1/ADR33 cells, and
that concentrations of BFA up to 320 gM are not directly
cytotoxic after a time period of 2-4 h. In short-term
experiments with the P-gp-negative MDR COR-L23/R cells
BFA was reported to be cytotoxic already at 40 giM and was
therefore notregarded as apotential MDR reverser, although it
did increase the cellular drug accumulation and the nuclear -
cytoplasmic ratio for anthracyclines (Rhodes et al., 1994). The
reason for this discrepancy remains to be elucidated, but we
cannot exclude that BFA toxicity is cell line dependent. It is
also possible that BFA provoked more cell detachment in the
sparse cultures used by Rhodes et al. (1994) than in the
confluent cultures in our protocol.
To provide new insights into the multifactorial nature of
MDR more functional probes addressed to non-P-gp-
mediated drug transport are needed. Genistein was recently
proposed as a probe for non-P-gp-related drug accumulation
defects, although cytotoxicity at the modulatory concentra-
tions of 100-300 ,UM was observed (Versantvoort et al, 1993).
Genistein appears to be a competitive inhibitor of anthracy-
cline transport attributed to the MRP efflux pump
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(Versantvoort et al., 1994). This mechanism could account
for the genistein-sensitive drug accumulation defects in the
MRP-positive PSNI/ADR33 cells presented here, and in a
variety of MRP-positive MDR cell lines (GLC4/ADR, SW-
1573/2R120, HT1080/DR4, HL60/ADR) described elsewhere
(Versantvoort et al., 1993). However, the reversal of DOX
resistance by genistein was reported also for the MRP-
negative K562/TPA cells, thereby indicating the existence of
target(s) different from MRP (Takeda et al., 1994).
Additionally, ATP depletion (Versantvoort et al., 1994) and
the inhibition of the G protein-linked secretory pathway
(Duan et al., 1994) were observed in cells exposed to genistein
at high concentrations.
BFA has not yet been studied extensively as a
chemomodifier of DOX resistance. Our data demonstrates
that BFA is capable of complete discrimination between
ADR extrusion pathways in MRP-positive PSNI/ADR33
and P-gp-positive H134AD cells. Its specificity and potency
seem to be close to those of genistein. The reversal of DOX
resistance by BFA in PSN1/ADR33 cells is optimal at 100-
320 giM, whereas in cells not selected for MDR the inhibition
ofvesicular traffic by BFA occurs already at 10 giM (Klausner
et al., 1992). This discrepancy raises the question of whether
BFA is a specific enough probe to implicate drug-trapping
vesicles in the mechanism of DOX extrusion. A striking
similarity between the inhibitory potency of BFA and
genistein in the MRP-positive PSN1/ADR33 cells would
suggest that BFA, by analogy to genistein (and verapamil),
might be a competitive inhibitor of the MRP efflux pump.
This assumption is in line with the concomitant activation of
MRP and the outward DOX transport sensitive to genistein,
BFA and verapamil. However, the inhibitory effects of
verapamil can also be attributed to membrane traffic
perturbations (Sehested et al., 1987). In addition, the above
explanation is not consistent with the opposite effects of BFA
and verapamil on DOX cytotoxicity in parental PSN1 cells
that displayed a low but detectable level of MRP. Secondly,
DOX extrusion in PSN1/ADR33 cells was sensitive to
fluoroaluminate, an agent which disrupts GTP-dependent
vesicular transport (Barr et al., 1991), and is unlikely to exert
preferential inhibition of MRP compared with P-gp when its
interference with ATP-binding sites is supposed. Thirdly,
nocodazole, an agent that can block the vesicular transport
by microtubule depolymerisation (Breitfeld et al., 1990),
inhibited substantially the DOX extrusion in the PSNI/
ADR33 but not H134AD cells. Finally, PSN1/ADR96 cells
adapted to 510 nM DOX retained BFA-sensitive DOX
accumulation defects whereas MRP declined. Hence, it
seems unlikely that BFA would target solely the MRP
transporter in this cell subline.
In the extensive literature now available on BFA its target
is thought to be the ARF GDP/GTP exchange factor,
specifically ascribed to G protein-controlled vesicular traffic
(Donaldson et al., 1992; Klausner et al., 1992). Interestingly,
the activated pool of G proteins in a GTP-bound form was
shown to resist low concentrations of BFA (Klausner et al.,
1992; Ktistakis et al., 1992). Therefore, elevated modulatory
concentrations of BFA in PSN1/ADR33 cells might indicate
an enriched pool of activated G proteins that trigger vesicular
exocytosis. In the view of this hypothesis, BFA-sensitive
vesicular transport could particularly sustain DOX resistance,
since lipophilic and weakly basic anthracyclines can be
trapped inside vesicular structures (Gervasoni et al., 1991;
Coley et al., 1993). Future studies should clarify whether the
model of vesicle-mediated drug transport is relevant to the
BFA/fluoroaluminate-sensitive mechanism of DOX extrusion
or whether BFA is an inhibitor of MRP. In this paper, we
focused primarily on reversal properties of G protein-
targeting agents in an effort to provide a rationale for
searching for novel functional probes of MDR not associated
with the P-gp transporter. Our preliminary tests have shown
a clear correlation (r>0.9) between the BFA reversal effects
and DOX resistance in a panel of P-gp-negative human
pancreatic tumour cell lines (Verovski et al., 1994). This is
further support for BFA as an appropriate tool to dissect the
mechanisms of DOX resistance not associated with the P-gp
efflux pump.
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